Drug intelligence / Profile preview

IBI-130

Development stage: Phase 2
Lead developer: Suzhou Innovent Biologics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IBI-130 is an antibody-drug conjugate (ADC) under development by Innovent Biologics for the treatment of advanced or metastatic solid tumors. The drug targets cancer cells expressing trophoblast cell surface antigen 2 (Trop-2), also known as tumor-associated calcium signal transducer 2, and delivers a cytotoxic payload directly to these cells. This targeted approach aims to improve efficacy while minimizing off-target toxicity. As of the latest updates, IBI-130 is in Phase II clinical trials for solid tumors in Australia and China.

Other names: IBI 130IBI130IBI-130

Targets

TOP1 (DNA Topoisomerase I)TACSTD2 (Tumor-associated calcium signal transducer 2)

Beyond the preview

Go deeper on IBI-130.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBI-130.

Explore the full profile